The transcription role of PML and the nuclear body

Nature Cell Biology

Volumn 2, Issue 5, 2000, Pages

  Zhong, S ^a   Salomoni, P ^a   Pandolfi, P P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR PROTEIN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; CANCER INHIBITION; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; GENETIC CODE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; CELL NUCLEUS; CHEMISTRY; GENETIC TRANSCRIPTION; PHYSIOLOGY; ULTRASTRUCTURE;

ANIMALS; CELL NUCLEUS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 0034186133     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/35010583     Document Type: Review

References (95)

1. Structure and origin of the acute promyelocytic leukaemia myl/RARalpha cDNA and characterization of its retinoid-binding and transactivation properties
2. The PML/RARalpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukaemia encodes a functionally altered RAR
3. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukaemia
4. Chromosomal translocation t(15;17) in human acute promyelocytic leukaemia fuses RARalpha with a novel putative transcription factor, PML
5. Deconstructing a disease: RARalpha, its fusion partners, and their rules in the pathogenesis of acute promyelocytic leukaemia
6. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukaemia in the mouse and its therapeutic implications
7. Nuclear dots: Actors on many stages
8. Identification of a novel nuclear domain
9. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
10. The t(15;17) translocation alters a nuclear body in a retinulc acid-reversible fashion
11. Retinoic acid regulates aberrant nuclear localization of PML-RARalpha in acute promyelocytic leukemic cells
12. Structure, organization, and dynamics of promyelocytic leukaemia protein nuclear bodies
13. Nuclear domain 10, the site of DNA virus transcription and replication
14. The nucleolus
15. The PML growth-suppressor has an altered expression in human oncogenesis
16. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body
17. The promyelocytic leukaemia gene product (PML) forms stable complexes with the retinoblastoma protein
18. A role for PML and the nuclear body in genomic stability
19. PML and Daxx participate in a novel nuclear pathway for apoptosis
20. Mutations in human ARF exon 2 disrupt its nucleolar localization and impairs its ability to block nuclear export of MDM 2 and p53
21. PML is critical for ND 10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1
22. Role of SUMO-1 modified PML in nuclear body formation
23. PlC1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia
24. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus
25. Identification of three major sentrinization sites in PML
26. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex
27. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3
28. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp 100 by PIC1/SUMO-1
29. The nuclear dot protein Sp 100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers
30. A new protease required for cell-cycle progression in yeast
31. Differential regulation of sentrinized proteins by a novel sentrin-specific protease
32. A novel cysteine-rich sequence motif
33. The RING finger domain: A recent example of a sequence-structure family
34. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukaemia (APL): Structural similarities with a new family of oncoproteins
35. PML/RAR homodimers: Distinct DNA binding properties and heteromeric interactions with RAR
36. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotain PML
37. The acute promyelocytic leukaemia-associated PML gene is induced by interferon
38. Acute promyelocytic leukaemia as a model for cross-talk between interferon and retinoic acid pathways: From molecular biology to clinical applications
39. The periphery of nuclear domain 10 (ND 10) as site of DNA virus deposition
40. The ability of herpes simplex virus type 1 immediate-early protein Vmw 110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication
41. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp 100 proteins, correlating with nuclear body disruption
42. Resistance to virus infection conferred by the interferon-induced promyelocytic leukaemia protein
43. A viral activator of gene expression functions via the ubiquitin-proteasome pathway
44. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells
45. The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies
46. Human papillomavirus DNA replication compartments in a transient DNA replication system
47. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and GAS element
48. IFN enhance expression of Sp 100, an autoantigen in primary biliary cirrhosis
49. Molecular cloning of a new interferon-induced PML nuclear body-associated protein
50. PML nuclear bodies are general targets for inflammation and cell proliferation
51. Role of PML in cell growth and the retinoic acid pathway
52. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation
53. Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class 1 antigens
54. Pml is essential for multiple apoptotic pathways
55. The promyelocytic leukaemia protein PML has a pro-apoptotic activity mediated through its RiNG domain
56. PML induces a novel caspase-independent death process
57. Cooperation between the RiNG + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival
58. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs)
59. Sequestration and inhibition of daxx-mediated transcriptional repression by PML
60. PML, a growth suppressor disrupted in acute promyelocytic laukaemia
61. Analysis of the growth and transformation suppressor domain of promyelocytic leukaemia gene, PML
62. The Bloom's syndrome gene product is homologous to RecQ helicases
63. Molecular genetics of Bloom's syndrome
64. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
65. Insights into the functions of BRCA1 and BRCA 2
66. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML may modulate a RING finger-Dependent cryptic transactivator function of PML
67. Transcriptional repression by the promyelocytic leukaemia protein, PML
68. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex
69. Composite co-activator ARC mediates chromatin-directed transcriptional activation
70. Ligand induction of a transcriptionally active thyroid hormone receptor co-activator complex
71. A retinoic acid-dependent tumour-growth suppressive transcription complex is the target of the PML-RARα and T 18 oncoproteins
72. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling
73. Effect of PML and PML-PAR on the transactivation properties and subcellular distribution of steroid hormone receptors
74. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukaemia protein
75. The promyelocytic leukaemia protein interacts with Sp 1 and inhibits its transactivation of the epidermal growth factor receptor promoter
76. Human T-cell leukaemia retrovirus-Tax protein is a repressor of nuclear receptor signaling
77. Intranuclear redistribution of SV 40T, p53, and PML in a conditionally SV 40T-immortalized cell line
78. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM 2 and p53 to U 1A-positive nuclear bodies associated with the PODs
79. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1
80. SUMO-1 modification activates the transcriptional response of p53
81. Role of CBP/P300 in nuclear receptor signalling
82. The CBP co-activator is a histone acetyltransferase
83. Regulation of activity of the transcription factor GATA-1 by acetylation
84. CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation
85. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltansferases
86. The putative nuclear receptor mediator Tif1alpha is tightly associated with euchromatin
87. Association of the Bloom Syndrome protein with Topoisomerase IIIalpha in somatic and meiotic cells
88. The promyelocytic leukaemia (PML) protein suppresses cyclin D 1 protein production by altering the nuclear cytoplasmic distribution of cyclin D 1 mRNA
89. The translation initiation factor elF 3-p 48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumour virus genome
90. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein
91. Interaction of Sp 100 with HP 1 proteins: A link between the promyelocytic leukaemia-associated nuclear bodies and the chromatin compartment
92. Identification and characterization of a leukocyte-specific component of the nuclear body
93. Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA
94. Chromatin components as part of a putative transcriptional repressing complex